 Doxorubicin
"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 2 | 4 | 6 | | 1993 | 1 | 3 | 4 | | 1994 | 0 | 3 | 3 | | 1995 | 1 | 2 | 3 | | 1996 | 1 | 0 | 1 | | 1997 | 3 | 2 | 5 | | 1998 | 1 | 5 | 6 | | 1999 | 1 | 3 | 4 | | 2000 | 2 | 2 | 4 | | 2001 | 1 | 7 | 8 | | 2002 | 1 | 2 | 3 | | 2003 | 0 | 2 | 2 | | 2004 | 2 | 1 | 3 | | 2005 | 0 | 2 | 2 | | 2006 | 2 | 4 | 6 | | 2007 | 3 | 4 | 7 | | 2008 | 0 | 5 | 5 | | 2009 | 4 | 5 | 9 | | 2010 | 2 | 4 | 6 | | 2011 | 4 | 5 | 9 | | 2012 | 1 | 7 | 8 | | 2013 | 2 | 8 | 10 | | 2014 | 2 | 10 | 12 | | 2015 | 3 | 5 | 8 | | 2016 | 5 | 6 | 11 | | 2017 | 2 | 10 | 12 | | 2018 | 0 | 6 | 6 | | 2019 | 1 | 10 | 11 | | 2020 | 2 | 5 | 7 | | 2021 | 4 | 7 | 11 | | 2022 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
McGinn O, Riley D, Finlay-Schultz J, Paul KV, Kabos P, Sartorius CA. Cytokeratins 5 and 17 Maintain an Aggressive Epithelial State in Basal-Like Breast Cancer. Mol Cancer Res. 2022 09 02; 20(9):1443-1455.
-
Bosire R, Fadel L, Mocsár G, Nánási P, Sen P, Sharma AK, Naseem MU, Kovács A, Kugel J, Kroemer G, Vámosi G, Szabó G. Doxorubicin impacts chromatin binding of HMGB1, Histone H1 and retinoic acid receptor. Sci Rep. 2022 05 16; 12(1):8087.
-
Li Y, Lofchy L, Wang G, Gaikwad H, Fujita M, Simberg D. PEGylated Liposomes Accumulate in the Areas Relevant to Skin Toxicities via Passive Extravasation across "Leaky" Endothelium. ACS Nano. 2022 04 26; 16(4):6349-6358.
-
Major A, Smith SM. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose? Clin Adv Hematol Oncol. 2021 Nov; 19(11):698-709.
-
Burke GAA, Minard-Colin V, Aupérin A, Alexander S, Pillon M, Delgado R, Zsíros J, Uyttebroeck A, Dartigues P, Miles RR, Kazanowska B, Chiang AK, Haouy S, Bollard CM, Csoka M, Wheatley K, Barkauskas DA, Adamson PC, Vassal G, Patte C, Gross TG. Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. J Clin Oncol. 2021 11 20; 39(33):3716-3724.
-
Hecht SL, Quach A, Gao D, Brazell A, Beltran G, Holbrook S, Gore L, Iguchi N, Malykhina A, Wilcox D, Cost NG. A prospective survey study of lower urinary tract dysfunction in childhood cancer survivors after vincristine and/or doxorubicin chemotherapy. Pediatr Blood Cancer. 2021 10; 68(10):e29226.
-
Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, D'Angelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, Olszewski AJ. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica. 2021 07 01; 106(7):1932-1942.
-
Cavalier AN, Clayton ZS, Hutton DA, Wahl D, Lark DS, Reisz JA, Melov S, Campisi J, Seals DR, LaRocca TJ. Accelerated aging of the brain transcriptome by the common chemotherapeutic doxorubicin. Exp Gerontol. 2021 09; 152:111451.
-
Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2021 06 01; 106(6):1705-1713.
-
Giddings EL, Champagne DP, Wu MH, Laffin JM, Thornton TM, Valenca-Pereira F, Culp-Hill R, Fortner KA, Romero N, East J, Cao P, Arias-Pulido H, Sidhu KS, Silverstrim B, Kam Y, Kelley S, Pereira M, Bates SE, Bunn JY, Fiering SN, Matthews DE, Robey RW, Stich D, D'Alessandro A, Rincon M. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nat Commun. 2021 05 14; 12(1):2804.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|